Clinical Trial Update: Safety and Pharmacokinetic Study of Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Administered Rectally [Phase 1]

View source ↗

Summary

Phase 1 safety and pharmacokinetic study of rectally administered Tenofovir Alafenamide/Elvitegravir in HIV infections completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Tenofovir alafenamide/elvitegravir (tenofovir alafenamide/elvitegravir)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2023-12-22